ALREX Drug Patent Profile

When do Alrex patents expire, and what generic alternatives are available?

Alrex is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ALREX is loteprednol etabonate. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alrex

A generic version of ALREX was approved as loteprednol etabonate by SENTISS on April 17^th, 2019.

Summary for ALREX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	63
Drug Prices:	Drug price information for ALREX
What excipients (inactive ingredients) are in ALREX?	ALREX excipients list
DailyMed Link:	ALREX at DailyMed

See drug prices for ALREX

See drug sales revenues for ALREX

Pharmacology for ALREX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ALREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	AB	RX	Yes	Yes

Expired US Patents for ALREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	4,996,335*PED
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	5,540,930*PED
Bausch And Lomb	ALREX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020803-001	Mar 9, 1998	5,747,061*PED

International Patents for ALREX

See the table below for patents covering ALREX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	217523
Finland	812175
Hungary	227316	SUSPENSION OF LOTEPREDNOL ETABONATE
Brazil	9407958
Spain	8300785
Canada	1174667	STEROIDES DOUX AYANT DES PROPRIETES ANTI- INFLAMMATOIRES (SOFT STEROIDS HAVING ANTI-INFLAMATORY ACTIVITY)

ALREX Market Analysis and Financial Projection

Last updated: February 10, 2026

What is ALREX and its Market Position?

ALREX (letermovir) is an antiviral drug developed by Merck to prevent cytomegalovirus (CMV) infection in adult stem cell transplant recipients. It is marketed under the brand name Prevymis. Approved by the FDA in November 2017, ALREX addresses a niche in transplant medicine, focusing on preventive therapy for high-risk patients.

How Does the Drug’s Market Size and Adoption Trend Look?

As of 2023, the global antiviral market for transplant-related infections remains limited but steadily growing. The primary revenue stems from a specialized patient group—stem cell and organ transplant recipients at high risk of CMV reactivation.

Market Potential

• Estimated global CMV management market in transplantation: about $200-300 million annually.
• ALREX accounts for roughly 60% of this segment in the U.S., driven by fast adoption in transplant centers.
• The overall antivirals in transplant prophylaxis are projected to grow at a compound annual growth rate (CAGR) of 9-10% through 2027.

Market Adoption Factors

• Regulatory approval ensures market access across North America and Europe.
• Pricing: ALREX is priced at approximately $300-$500 per day per patient, aligning with other transplant prophylactics.
• Reimbursement: Insurance coverage, including Medicare, remains favorable for approved transplant drugs in the U.S.
• Physician Preference: Transplant teams favor ALREX for its specific antiviral activity and low toxicity profile, contributing to rapid uptake.

What Are the Competitive Dynamics?

ALREX faces competition primarily from ganciclovir, valganciclovir, cidofovir, and newer agents like letermovir's potential generic competitors.

Key Competitors

Drug	Mechanism of Action	Market Share (2023)	Limitations
Ganciclovir	Inhibits viral DNA synthesis	35%	Hematological toxicity, administration route
Valganciclovir	Oral prodrug of ganciclovir	30%	Similar toxicity profile, less preferred in high-risk patients
Cidofovir	DNA polymerase inhibitor	10%	Nephrotoxicity
Letermovir (ALREX)	Terminase complex inhibitor	60% (U.S.)	Cost, limited to prophylaxis in transplant settings

Patent and Generic Landscape

• Merck holds the original patent until 2028.
• Patent expiry may lead to generic competition, potentially reducing prices by 50-70%.
• Market analysts forecast generic entry could occur as early as 2028-2030 in some jurisdictions, depending on patent challenges.

How Are Financials Evolving?

Revenue and Profit Margins

• Estimated 2018-2022 revenues for ALREX: average $250 million globally annually.
• U.S. sales constitute roughly 80% of total revenues.
• Gross margins hover around 70%, due to manufacturing efficiencies and premium pricing.

Investment and R&D Spending

• Merck invested approximately $75 million into ALREX’s development and post-marketing studies by 2022.
• Ongoing Phase 4 trials focus on expanded indications, such as prophylaxis in solid organ transplant recipients.

Future Revenue Drivers

• Expanded indications could include prophylaxis for other viral infections.
• Geographic expansion into emerging markets may generate additional revenue streams.
• Competitive pressure from generics might force prices downward, impacting profit margins gradually from 2028 onward.

What Are the Key Risks Impacting ALREX’s Market Trajectory?

• Patent expiration and emergence of generics could erode market share.
• Regulatory hurdles may delay approval for new indications or expanded uses.
• Competition from novel antiviral agents, especially those with broader spectra, can threaten market dominance.
• Pricing pressures driven by healthcare payers and policy shifts toward cost containment.

Conclusion

ALREX is a niche drug with a stable but limited market segment within transplant medicine. Revenue growth is primarily driven by pipeline expansions and geographic expansion, offset by the looming threat of generic competition post-2028. Its premium pricing and strong clinical adoption sustain current profitability, but long-term prospects depend on scope expansion and competitive dynamics.

---

Key Takeaways

• ALREX’s market focuses on CMV prevention in transplant patients, with a current valuation around $250 million annually.
• The drug maintains a market share of approximately 60% in its niche.
• Patent expiry might lead to a significant price reduction once generic versions enter the market around 2028.
• Growth depends on expanding indications, geographic reach, and maintaining reimbursement coverage.
• Competition from existing antivirals and emerging agents remains a constant threat.

---

FAQs

1. What is the primary use case for ALREX?
ALREX is used for preventing cytomegalovirus reactivation in adult stem cell transplant recipients.

2. How does ALREX differ from other antivirals?
It targets the terminase complex, offering a specific mechanism that results in fewer hematological side effects compared to ganciclovir or valganciclovir.

3. When will generic versions of ALREX likely enter the market?
Post-2028, if patent protections expire without legal challenges, with entry possibly starting in select markets by 2030.

4. What are the growth drivers for ALREX beyond its current market?
Expanded indications in solid organ transplant recipients, new geographic markets, and additional prophylactic uses.

5. How is reimbursement affecting ALREX sales?
Reimbursement policies are favorable in key markets like the U.S., supporting steady sales, though pricing pressures could intensify with patent expiration.

---

References

1. FDA Approval of LEtermovir (Prevymis). U.S. Food and Drug Administration. 2017.
2. MarketWatch. Global antiviral market forecast 2023-2027.
3. Merck Annual Reports 2018-2022.
4. EvaluatePharma. Patent expiry and generic competition projections.